GoldenGolden
Mission Bio

Mission Bio

Mission Bio is a South San Francisco based company that develops single-cell DNA analysis and precision genomics.

Funding

In October 2017 Mission Bio announced that it had completed a $10 million Series A financing round. The financing will support the launch of the firm's single-cell DNA analysis platform, Tapestri. Mayfield Fund, a Silicon Valley venture capital firm, led the round.

On December 13, 2018, Mission Bio announced it had completed its $30 million Series B round. Investors include Agilent Technologies, Cota Capital, LAM Capital, and Mayfield, bringing the total amount raised by the company to more than $50 million.

Tapestri

Tapestri is able to identify single-nucleotide variants (SNVs) and indels, two types of genetic variants that are relevant to precision medicine. Tapestri is a targeted single-cell DNA sequencing platform, enabling detection of heterogeneity in disease progression and treatment response. Application areas include blood cancers, solid tumors, and genome editing validation. The platform includes an instrument, consumables, and analysis software, which integrate with existing NGS workflows.

Timeline

April 20, 2021
Mission Bio announces the launch of its Pharma Assay Development (PAD) services to accelerate biomarker discovery and cell and gene therapy development pipelines for biopharma customers.
April 8, 2021
Mission Bio announces snags Thermo Fisher veteran Yan Zhang as a new CEO of the company.
August 2020
Mission Bio raised its largest round yet in August 2020, a $70 million series C financing tagged to scale up its single-cell multi-omics platform, known as Tapestri.
May 15, 2019
Mission Bio, Inc. announces the publication of a study demonstrating Tapestri®
March 7, 2019
Mission Bio Launches TapestriR Designer, the First Automated On-Demand Cloud Tool for Targeted Single-Cell DNA Custom Panels

Mission Bio, the pioneer in targeted single-cell DNA analysis and precision genomics, today announced the launch of Tapestri Designer, the first-ever automated, cloud-based tool for designing targeted single-cell DNA custom panels.

December 13, 2018
Mission Bio, Inc. announced it raised $30 million in Series B funding from Agilent Technologies (NYSE:)
December 13, 2018
Mission Bio raises a $30,000,000 series B round from Agilent Technologies.
December 2018
Mission Bio raises a $30,000,000 series B round from Agilent Technologies, Cota Capital, LAM Capital and Mayfield Fund.
October 2017
Mission Bio raises a $10,000,000 series A round from Mayfield Fund.
2012
Mission Bio was founded.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Mission Bio Inc funding round, December 2018
30,000,000
December 2018
3 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Dennis Eastburn

CSO and Co-founder

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Gail Dutton
April 21, 2021
BioSpace
Mission Bio just launched its Pharma Assay Development (PAD) service, enabling its customers to obtain early access services based on the newest technologies as well as on its existing products.
Mission Bio
April 20, 2021
www.prnewswire.com:443
/PRNewswire/ -- Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced the launch of its Pharma Assay...
BioSpace
April 20, 2021
BioSpace
Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the launch of its Pharma Assay Development services to accelerate biomarker discovery and cell and gene therapy development pipelines for biopharma customers.
Alex Keown
April 8, 2021
BioSpace
She succeeds Mission Bio's current chief executive officer Charlie Silver, who will shift into an advisory role with the company he co-founded.
BioSpace
April 8, 2021
BioSpace
Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the appointment of Yan Zhang to the role of CEO.
Mission Bio
April 8, 2021
www.prnewswire.com:443
/PRNewswire/ -- Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced the appointment of Yan Zhang to the role...
Amirah Al Idrus
April 7, 2021
FierceBiotech
After a decade at Thermo Fisher Scientific, Yan Zhang is taking the helm of Mission Bio from Charlie Silver. Silver, the company's co-founder and CEO who led the team that developed company's platform and took it to market, will move into an advisory role.
Mission Bio
March 11, 2021
www.prnewswire.com:443
/PRNewswire/ -- Mission Bio, the life sciences company delivering single-cell resolution multi-omics tools to accelerate discoveries and improve time-to-market...
October 30, 2020
WebWire
Mission Bio, Inc. today announced the launch of a complete Tapestri® Single-cell Multi-omics Solution, the most comprehensive single-cell multi-omics platform on the market. With a new instrument, single-cell multi-omics reagent kits, TotalSeq-DTM antibody content from BioLegend, and visualization software, the complete package provides layered insight into multiple analytes across all blood cancers, reducing drug development time and cost by at least half. The company is partnering with...
August 20, 2020
WebWire
Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omic analysis, today announced the publication of a study demonstrating the power of its Tapestri® Platform to detect clonal evolution and residual leukemic cells in pediatric T-cell acute lymphoblastic leukemia (T-ALL). The study, published in Blood, was led by Jan Cools, Ph.D. at VIB & KU Leuven (Leuven, Belgium), and underscores the power of single-cell analysis to improve treatment strategies and prognosis ba...
August 13, 2020
WebWire
Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced $70 million in its Series C financing led by Novo Growth, the growth equity arm of Novo Holdings. Soleus Capital also joins the round, along with earlier investors Mayfield, Cota, and Agilent, bringing the company's total funding to more than $120 million. To support Mission Bio's rapid growth, the funds will scale its single-cell multi-omics technology, the Tapestri® Platform, to e...
Darrell Etherington
August 13, 2020
TechCrunch
California-based startup Mission Bio has raised a new $70 million Series C funding round, led by Novo Growth and including participating from Soleus Capital and existing investors Mayfield, Cota and Agilent. Mission Bio will use the funding to scale its Tapestri Platform, which uses the company's work in single-cell multi-omics technology to help optimize clinical [...]
April 23, 2020
WebWire
Mission Bio, Inc., the pioneer in high-throughput single-cell multi-omics and DNA analysis today announced a partnership with Agilent Technologies, a global leader in life sciences, diagnostics and applied chemical markets. The two companies have entered a co-marketing agreement to drive adoption of Mission Bio's Tapestri Platform, the industry's first and only multi-omic device to analyze both DNA and protein at the single-cell level. North America is the largest single-cell genome seq...
April 16, 2020
WebWire
Mission Bio, Inc., the pioneer in high-throughput single-cell multiomics and DNA analysis, today announced the publication of a study demonstrating the power of its Tapestri® Platform to help characterize relapse-driving cells in patients with Acute Myeloid Leukemia (AML). The study of 81 patients, led by researchers at MD Anderson Cancer Center and Monash University in Melbourne, Australia, highlights co-occurring therapy-driven mutations that stand to impact future treatment strategies...
March 12, 2020
WebWire
Mission Bio, Inc., the pioneer in high-throughput single-cell multiomics and DNA analysis, today announced the publication of a study demonstrating the power of its Tapestri® Platform to help identify and characterize relapse-driving cells. Sequencing over 300,000 cells, the 38-sample study was led by Ravi Majeti, M.D., Ph.D. and his team at Stanford University and published in Blood Advances. It is the first-ever study using single-cell DNA analysis to track minimal/measurable residual d...
November 6, 2019
WebWire
Mission Bio, Inc., the pioneer in high-throughput single-cell DNA analysis and precision genomics, today announced its expansion into single-cell multi-omics. The company's proprietary technology, the Tapestri Platform, is now the first-ever single-cell multi-omic platform capable of detecting DNA and protein changes simultaneously from the same cell -- a capability necessary for the development of impactful precision therapies. The company has partnered with BioLegend, a global leader in...
October 10, 2019
WebWire
Mission Bio, Inc., the pioneer in high-throughput single-cell DNA analysis and precision genomics, today announced that it has been awarded a grant from the National Cancer Institute (NCI) Small Business Innovation Research (SBIR) program to develop more advanced methods of quantifying molecular minimal residual disease (MRD) in acute myeloid leukemia (AML). In partnership with Dr. Jerry Radich of Fred Hutchinson Cancer Research Center, the project will leverage Mission Bio's Tapestri Pla...
August 22, 2019
WebWire
Mission Bio, Inc., the pioneer in targeted single-cell DNA analysis and precision genomics, today announced the launch of Copy Number Analysis, extending Copy Number Variation (CNV) capabilities to its Tapestri Platform with no changes to the current workflow. With this latest capability, Mission Bio's Tapestri® Platform now stands as the first and only commercial platform for single-cell DNA analysis, with comprehensive insight into mutations a
May 15, 2019
WebWire
Mission Bio, Inc., the pioneer in high-throughput single-cell DNA analysis and precision genomics, today announced the publication of a study demonstrating the power of its Tapestri® Platform to help predict and prevent cancer progression. The study, published in Cancer Discovery, is the first-ever study using single-cell DNA analysis to reveal how cancer evolves in response to targeted treatment, leading to therapy resistance and disease progression in AML patients., , , , Although new ta...
April 25, 2019
WebWire
Mission Bio, Inc., the pioneer in high-throughput single-cell DNA analysis and precision genomics, today announced the addition of three key members to its executive team. Darrin Crisitello joins the Mission Bio team as Chief Commercial Officer with over 19 years of experience in commercial leadership and business development. Previously, Crisitello led the global clinical teams at Color Genomics and [url=https://
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.